Published online Nov 26, 2019. doi: 10.4252/wjsc.v11.i11.957
Peer-review started: May 27, 2019
First decision: July 31, 2019
Revised: September 2, 2019
Accepted: September 13, 2019
Article in press: September 13, 2019
Published online: November 26, 2019
Core tip: Cell-based therapy using autologous mesenchymal stem cells represents a perspective approach for the treatment of so far incurable degenerative retinal diseases. However, the therapeutic potential of mesenchymal stem cells strongly depends on the cytokine environment, where these cells are delivered. In this study, we discuss recent knowledge regarding the interactions and interplay among cytokines produced by cells of the diseased retina, inflammatory immune cells and therapeutically administered mesenchymal stem cells. We suggest that these interactions among cytokines and growth factors occurring in the microenvironment of the diseased retina could be critical for the outcome of the stem cell-based therapy for retinal disorders.